Some of these in vitro results were confirmed in a xenograft model in vivo, providing for the first time the concept of proof that supraphysiological pulsed T supplementation induces a significant reduction in both tumor volume and AR, p-ARser81, PSA and CDK1 staining with respect to supraphysiological continuous T supplementation or T levels in the range of hypogonadism. This evidence concerns the gene CDK1 and neoplasm.